Mineralys Therapeutics, Inc. Share Price

Mineralys Therapeutics, Inc. Share Price

NASDAQ: MLYS | Small Cap
$21.23
-$0.18 (-0.84%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Mineralys Therapeutics, Inc. Stock Performance

Open
$21.43
Prev. Close
$21.41
Circuit Range
N/A
Day Range
$21.11 - $22.44
Year Range
$20.13 - $47.60
Volume
1,09,194
Average Traded
$21.68

Mineralys Therapeutics, Inc. Share Price Today

As of 30 October 2026, Mineralys Therapeutics, Inc.'s share price is $21.23. The stock opened at $21.43, compared to its previous close of $21.41. During today's trading session, Mineralys Therapeutics, Inc.'s share price traded between $21.11 and $22.44, with an average price of $21.77. Over the past 52 weeks, the stock has recorded a high of $47.60 and a low of $20.13. In terms of performance, Mineralys Therapeutics, Inc.'s share price has declined by 20.50% over the last six months and is down 48.00% on a year-on-year basis.

Mineralys Therapeutics, Inc. Share Price Chart

Line chart of the Mineralys Therapeutics, Inc. price trend over the selected period. The price fell overall, ranging from 21.11 to 22.48, ending at 21.24.
$21.11$22.44
L
Show Current Price
H

Mineralys Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$1.44B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-3.95
Revenue (TTM)
$0.00
Return On Equity (TTM)
-63.45%
Profit Margin
N/A
Debt to Equity
0.18
Quarterly Earnings Growth YoY
-552.78%

Mineralys Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$36.93-$32.23-$39.34-$241.07
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A12.73%-22.06%-512.79%

Mineralys Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars202320242025
Revenue$0.00$0.00$0.00
Net Profit-$71.90-$177.81-$154.65
Net Profit MarginN/AN/AN/A
Income ChangeN/A-147.30%13.03%

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Mineralys Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$24.91
$21.25
-15.61%
Sep 2026
$25.43
$25.18
-3.17%
Aug 2026
$25.48
$26.00
+1.94%
Jul 2026
$26.63
$25.50
-5.54%
Jun 2026
$31.08
$27.00
-14.12%
May 2026
$27.97
$31.44
+17.73%
Apr 2026
$28.22
$26.70
-1.38%
Mar 2026
$28.87
$27.08
-7.51%
Feb 2026
$31.27
$29.28
-5.12%
Jan 2026
$36.30
$30.86
-14.89%
Dec 2025
$43.03
$36.26
-16.01%
Nov 2025
$40.67
$43.17
+5.74%

MLYS Share Price FAQs